42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®

***AGENDA WORK IN PROGRESS***

How Do I Choose a Therapy for Frontline CLL?

Emerging Advancements in CLL: CAR T-Cell Therapies and Novel BTKi

Evolving Options for Use of BTKi in MCL: Evidence-Based Insights

Expanded Options for Follicular Lymphoma in 2024: A Focus on BTKi, CAR-T, and Bispecific Antibodies

DLBCL: A Risk-Based Approach to Frontline Therapy

Real-World Evidence: Utilizing CAR T-Cell Therapies and Bispecific Antibodies in DLBCL

Tailoring CML Treatment Along the Treatment Continuum

Ambulatory Care Delivery for Cellular Therapy: Managing CRS, ICANS, and Other Challenges

ONS ASCO Antineoplastic Safety Standards and Safe Handling of Hazardous Drugs

Urgent Care Setups in Oncology -- How Do They Vary Across the Country?